Use of bone-modifying agents for bone metastases from neuroendocrine neoplasms: a single-centre audit
5 affiliations
- 1Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK
- 2National Diabetes & Endocrine Centre, The Royal Hospital, Muscat, Oman
- 3Department of Oncology, Imperial College Healthcare NHS Trust, London, UK
- 4Division of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK
- 5Department of Surgery and Cancer, Imperial College London, London, UK
Abstract
Bone metastases in neuroendocrine neoplasms are uncommon but cause significant morbidity. A recent Italian survey of 320 patients with neuroendocrine neoplasms and bone metastases reported skeletal-related events in 23% and bone-targeted agent use in 31%, highlighting limited evidence for bone-modifying agents. We identified adults with confirmed or clinically suspected neuroendocrine bone involvement who received a bone-modifying agent at a UK tertiary centre (January 2019–September 2024), using institutional prescribing records. Demographic, tumour, treatment, and toxicity data were extracted from records. Twenty-two patients received treatment (denosumab 17 (77%); zoledronic acid 5 (23%)). Most (91%) had grade 1–2 tumours; 64% had gastroenteropancreatic primaries. Bone metastases were synchronous in 45% and widespread (more than three lesions) in 73%. At diagnosis, 23% were symptomatic; during follow-up, 77% developed pain, high blood calcium, or a skeletal-related event. Skeletal-related events, a composite of pathological fracture, spinal cord compression, radiotherapy to bone, or orthopaedic surgery, occurred in 41% (radiotherapy alone in 36%); pain-relieving medication was used universally. Treatment was mainly given every 12 weeks (median six doses). Low blood calcium occurred in 9% and osteonecrosis of the jaw in 5%; dental assessment before therapy was recorded in only 9%. Treatment use was heterogeneous, reflecting a lack of disease-specific guidelines, and recorded toxicity was infrequent and generally manageable, although exposure varied s. Our findings highlight the need for prospective studies and structured registries to clarify treatment use, dosing, and impact on quality of life and prognosis.
Related
- Characterizing bone metastases and skeletal‐related events in patients with well‐differentiated neuroendocrine neoplasms utilizing 68Gallium‐DOTATATE positron emission tomography
- Editorial: Unveiling the complexity of neuroendocrine neoplasms: biomarkers, classification, and translational perspectives
- Spotlight on Small-Cell Lung Cancer and Other Lung Neuroendocrine Neoplasms.
- Primary Hepatic Neuroendocrine Neoplasms: Systematic Review and Expert Pathologist Reappraisal Using the WHO 6th Edition Framework
- IASLC Update on Classification of Pulmonary Neuroendocrine Neoplasms
BibTeX
@article{osman2026bonemodifying,
title = {{Use of bone-modifying agents for bone metastases from neuroendocrine neoplasms: a single-centre audit}},
author = {Wessam Osman and Preetha Aravind and Hemanth Prabhudev and Jeannie Todd and Ramona Nistor and Antonio D’Alessio and Rohini Sharma and Tami Grunewald and Florian Wernig},
journal = {Endocrine Connections},
year = {2026},
month = oct,
doi = {10.1530/ec-26-0252},
url = {https://doi.org/10.1530/ec-26-0252},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Use of bone-modifying agents for bone metastases from neuroendocrine neoplasms: a single-centre audit
AU - Wessam Osman
AU - Preetha Aravind
AU - Hemanth Prabhudev
AU - Jeannie Todd
AU - Ramona Nistor
AU - Antonio D’Alessio
AU - Rohini Sharma
AU - Tami Grunewald
AU - Florian Wernig
PY - 2026
DA - 2026/10/26
JO - Endocrine Connections
DO - 10.1530/ec-26-0252
UR - https://doi.org/10.1530/ec-26-0252
AB - Bone metastases in neuroendocrine neoplasms are uncommon but cause significant morbidity. A recent Italian survey of 320 patients with neuroendocrine neoplasms and bone metastases reported skeletal-related events in 23% and bone-targeted agent use in 31%, highlighting limited evidence for bone-modifying agents. We identified adults with confirmed or clinically suspected neuroendocrine bone involvement who received a bone-modifying agent at a UK tertiary centre (January 2019–September 2024), using institutional prescribing records. Demographic, tumour, treatment, and toxicity data were extracted from records. Twenty-two patients received treatment (denosumab 17 (77%); zoledronic acid 5 (23%)). Most (91%) had grade 1–2 tumours; 64% had gastroenteropancreatic primaries. Bone metastases were synchronous in 45% and widespread (more than three lesions) in 73%. At diagnosis, 23% were symptomatic; during follow-up, 77% developed pain, high blood calcium, or a skeletal-related event. Skeletal-related events, a composite of pathological fracture, spinal cord compression, radiotherapy to bone, or orthopaedic surgery, occurred in 41% (radiotherapy alone in 36%); pain-relieving medication was used universally. Treatment was mainly given every 12 weeks (median six doses). Low blood calcium occurred in 9% and osteonecrosis of the jaw in 5%; dental assessment before therapy was recorded in only 9%. Treatment use was heterogeneous, reflecting a lack of disease-specific guidelines, and recorded toxicity was infrequent and generally manageable, although exposure varied s. Our findings highlight the need for prospective studies and structured registries to clarify treatment use, dosing, and impact on quality of life and prognosis.
SN - 2049-3614
ER -